Curtis et al @RADoctor . IL6i more effective than conventional immunomodulators in refractory PMR. More likely to discontinue GC (HR 1.32), minimal GC (<2mg) (HR 1.30). @RheumNow #ACR22 Abstr#1547 https://t.co/uzSzrLQ9cB https://t.co/G4pEkOgYm2